CAN
ATXI

Cetera Advisor Networks’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Cetera Advisor Networks’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10
Closed -$3K – 2191
2022
Q2 		$3K Buy
+10
New +$3.85K ﹤0.01% 2055

Other funds holding ATXI

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Cetera Advisor Networks's ATXI Position: Q3 2022 in Review

Cetera Advisor Networks sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q3 2022, closing a stake of 10 shares — an estimated $3K sold.

Cetera Advisor Networks first reported a position in ATXI in Q2 2022 and held it in 1 quarter. The position peaked at $3K in Q2 2022. 10 funds tracked by Wall St. Rank hold ATXI as of Q3 2022.

  • Cetera Advisor Networks reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Cetera Advisor Networks sold 10 Avenue Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $3K.
  • Cetera Advisor Networks first reported a position in Avenue Therapeutics, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Cetera Advisor Networks's Avenue Therapeutics, Inc. Common Stock position peaked at $3K in Q2 2022.
  • 10 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Cetera Advisor Networks's 13F filing for Q3 2022, filed 14 Nov 2022.